A First-in-Human Phase 1 Trial of NX-2127, a First-in-Class Bruton's Tyrosine Kinase (BTK) Dual-Targeted Protein Degrader with Immunomodulatory Activity, in Patients with Relapsed/Refractory B Cell Malignancies
Year: 2023
Type: conference-abstract
Source: Blood
Authors: Alexey Danilov, Michael T. Tees, Krish Patel, William G. Wierda, Manish Patel, Ian W. Flinn, Tahir Latif, Weiyun Ai, Meghan C. Thompson, Michael L. Wang, Clare Sun, Deborah M. Stephens, Michael J Thirman, Melissa Gessner, Johannes Wolff, Amanda Schwab, May Tan, Daniel Chan, Erin Meredith, Adrian Wiestner
Institutions: City Of Hope National Medical Center, Colorado Blood Cancer Institute, Presbyterian St. Luke's Medical Center, The University of Texas MD Anderson Cancer Center, Tennessee Oncology, University of Cincinnati, University of Cincinnati Medical Center, University of California, San Francisco, Memorial Sloan Kettering Cancer Center, National Institutes of Health, National Heart, Lung, and Blood Institute, University of Utah, Huntsman Cancer Institute, University of Chicago, Nurix (United States)
Language: English
Subfield: Genetics
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4389232285